d-wise and Whitespace partner on clinical data analytics solutions

| by |

UX-led innovation proves strategic to clinical trial acceleration

Pharmaceutical industry sees clear ROI in cloud-based, open-source statistical computing environments

Raleigh, North Carolina and Geneva, Switzerland, November 03, 2020: d-wise, the preferred advisor and implementation partner for clinical analysis technology, and Whitespace, a global leader in enterprise user experience (UX) design and development, are teaming up to drive innovation in statistical computing environment (SCE) solutions for the world’s largest life science companies. SCE systems manage the versioning, security, and integrity of data, programs, and outputs used in clinical data analysis.

Leveraging their combined expertise in clinical data analytics, cloud architecture, open-source software, and human-centered design, d-wise and Whitespace are collaborating with Big Pharma to deliver compliant, high-performance SCEs that are designed to optimize the user experience, provide agile data exploration, and enable controlled programming for the regulated clinical trial process.

An outcome of this collaboration is d-wise’s Aspire initiative, a modular framework of transferable technologies that reduces the time and cost associated with customization and reinvention. In partnership with Whitespace, d-wise aims to bring Aspire implementations to market for top-30 pharmaceutical companies starting in 2021.

“Cloud computing and the rapid adoption of open-source technologies like R and Python are driving the industry to replace legacy SCE systems,” said Sam Warden, VP Consulting, Europe for d-wise. “Our vision is to help the world’s leading pharmaceutical companies focus less on technology and more on telling the story of science. This means building automated, validated, scalable, and intuitive solutions that enable data scientists and biostatistical analysts to explore with agility and deliver with rigor.”

“User adoption is a major factor in the successful replacement of legacy systems of this scale and complexity,” said Julia Borkenhagen, Chief Experience Officer for Whitespace. “The deep domain expertise that d-wise brings to the table, combined with Whitespace’s enterprise UX approach, is a winning formula that takes clients on a journey from discovery and design through to development and delivery in record time. Our collaboration is further proof that the enterprise is fertile ground for innovation and human-centered transformation.”

Sam Warden and Julia Borkenhagen will be leading an innovation workshop at PHUSE EU Connect 2020 on November 9th. For more information about their workshop and to register for the event, please visit https://www.d-wise.com/blog/state-of-the-clinical-analytics-infrastructure-phuse-sce-workshop-recap.

About d-wise

The world’s largest life science companies trust d-wise to lead strategy and modernization of validated systems and technologies for clinical analytic environments. These solutions provide performance and flexibility for pivotal trial and real-world data analysis while maintaining validation requirements. www.d-wise.com

About Whitespace

Whitespace is a global leader in enterprise user experience. Fortune 1000 brands, including several of the world’s foremost life science companies, trust Whitespace to design and build customer and employee experiences that drive human-centered business transformation. www.whitespace.ch

Press contacts

  • Mike Kolzet, VP Strategic Marketing, mike[dot]kolzet[at]d-wise[dot]com
  • Lise Melanjoie-dit-Savoie, VP Business Development, lise[at]whitespace[dot]ch